Clinical trial
A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children…
NCT00435227 · MedImmune LLC, Industry · Terminated
Key facts
| NCT number | NCT00435227 |
|---|---|
| Title | A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness |
| Official title | A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate a Single Intramuscular Dose of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), for the Outpatient Treatment of Children With RSV Illness |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Participants Less Than 12 Months of Age With RSV Illness |
| Intervention type | Biological, Other |
| Interventions | Motavizumab, Placebo |
| Enrollment | 12 |
| Start date | Mar 20, 2007 |
| Primary completion | May 31, 2008 |
| Completion | May 31, 2008 |
| First posted | Feb 14, 2007 |
| Last update posted | Aug 17, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: